hackint0sh/New-Dataset huggingface dataset:
Aims: Clinical reasoning is a core nursing competency that involves analyzing patient-related data and providing appropriate nursing practices. Simulation-based education is effective in improving the clinical reasoning competencies and communication skills of nursing students. This study aimed to verify the effectiveness of virtual simulation-based education. conditions: Clinical Reasoning conditions: Communication conditions: Development, Human studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This quasi-experimental study used a single-group pretest-posttest design to verify the effectiveness of virtual simulation-based education for undergraduate nursing students. primaryPurpose: OTHER masking: NONE count: 37 type: ACTUAL name: virtual simulation-based education program measure: Nurses Clinical Reasoning Scale measure: Communication Skills Scale sex: ALL minimumAge: 20 Years maximumAge: 28 Years stdAges: ADULT facility: Tongmyong Unoversity city: Busan zip: 48520 country: Korea, Republic of lat: 35.10278 lon: 129.04028 hasResults: False
nctId: NCT06373159 id: 22643 briefTitle: An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan overallStatus: ACTIVE_NOT_RECRUITING date: 2024-04-10 date: 2024-09-30 date: 2024-09-30 date: 2024-04-18 date: 2024-04-18 name: Bayer class: INDUSTRY briefSummary: This is an observational study in which data already collected from people with sepsis (blood poisoning) and/or disseminated intravascular coagulation (DIC) are studied.
In this study, only available data from routine care are collected. conditions: Sepsis conditions: Disseminated Intravascular Coagulation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 5740 type: ESTIMATED name: No study intervention measure: Incidence of DIC assessed at 14 days, 21 days and 28 days of the patient follow up measure: Distribution of JAAM DIC score measure: Distribution of ISTH DIC score measure: Distribution of MHLW DIC score measure: Distribution of SOFA score measure: Days from sepsis diagnosis to the onset of DIC measure: Number of participants per clinical characteristics measure: Number of participants per DIC treatment patterns in patients with sepsis-associated DIC following the onset of DIC measure: Incidence rates of clinical outcomes assessed in patients with sepsis-associated DIC measure: Cumulative incidences of clinical outcomes assessed in patients with sepsis-associated DIC measure: Number of participants per clinical characteristics in subgroup of patients who developed sepsis-associated DIC measure: Number of participants per treatment patterns in subgroup of patients who developed sepsis-associated DIC measure: Incidence rates of clinical outcomes in subgroup of patients who developed sepsis-associated DIC measure: Number of participants per clinical characteristics after the onset of DIC in patients with non-sepsis-associated DIC measure: Number of participants per treatment patterns after the onset of DIC in patients with non-sepsis-associated DIC measure: Incidence rates of clinical outcomes after the onset of DIC in patients with non-sepsis-associated DIC sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bayer city: Tokyo zip: 100-8265 country: Japan lat: 35.6895 lon: 139.69171 hasResults: False
nctId: NCT06373133 id: 2024 (82) briefTitle: SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-11-01 date: 2026-11-01 date: 2024-04-18 date: 2024-04-18 name: West China Hospital class: OTHER briefSummary: To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer. conditions: Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: SHR-8068 name: Adebrelimab name: BP102 measure: Dose-limiting toxicity measure: PFS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373120 id: QX20231057-X-1 briefTitle: Interventional Ventricular Assist System for PCI in CHIP Patients acronym: REC-CHIPMCS overallStatus: RECRUITING date: 2024-03-01 date: 2025-03-30 date: 2025-04-30 date: 2024-04-18 date: 2024-04-18 name: Xijing Hospital class: OTHER briefSummary: In patients with complex coronary artery disease (CAD), determining the optimal revascularization strategy (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) remains a challenge. These high-risk patients pose an extreme surgical risk. However, with the development of new interventional techniques and materials, PCI is a good alternative to CABG and is referred to as complex high-risk indicated PCI (CHIP).
There are several mechanical circulatory support (MCS) systems available, i.e., intra-aortic balloon counterpulsation (IABP), Impella, TandemHeart, and veno-arterial extracorporeal membrane oxygenation (VA-ECMO). These MCS have been widely studied in patients with acute myocardial infarction (MI) complicated by cardiogenic shock and showed conflicting results. However, studies regarding the use of MCS in the setting of CHIP are much less abundant and no randomized study has compared Impella with VA-ECMO in CHIP patients.
The aim of the study is to evaluate the effectiveness of interventional ventricular assist system (CorVad) compared to the venoarterial extracorporeal membrane oxygenation (VA-ECMO) system in providing circulatory support for complicated and high-risk patient with indications for PCI. conditions: High-Risk Percutaneous Coronary Intervention (High-risk PCI) conditions: Left Ventricular Assist Devices studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, 1:1 randomized, controlled, multicenter trial to assess effectiveness and safety of CorVad compared to VA-ECMO in complicated and high-risk patient with indications for PCI primaryPurpose: TREATMENT masking: SINGLE maskingDescription: A blinded and independent clinical event adjudication committee will adjudicate all primary and secondary outcomes whoMasked: OUTCOMES_ASSESSOR count: 262 type: ESTIMATED name: CorVad name: VA-ECMO measure: Major adverse event measure: All-cause death measure: Stroke measure: Myocardial infarction measure: Revascularization measure: Cardiovascular hospitalization measure: MCS-ARC defined type 3, 4, 5 bleeding measure: Acute kidney injury measure: Serious device-related adverse events measure: Cardiopulmonary resuscitation measure: Hospitalization time measure: Intensive care unit (ICU/CCU) stay time measure: ECMO/Corvad utilization time measure: Hemodynamic disorder measure: Transfusion rate measure: Units of transfusion measure: Device-related composite endpoint (DoCE) measure: Patient-related composite endpoint (PoCE) measure: Net adverse clinical events measure: Cardiac death measure: Ischemic stroke measure: Hemorrhagic stroke measure: Transient ischemic attack measure: Target vessel myocardial infarction measure: Target lesion revascularization measure: Target vessel revascularization measure: Clinically and physiologically driven target lesion revascularization (CPI-TLR) measure: Rehospitalization measure: MCS-ARC type 2 bleeding measure: Puncture complications measure: Aortic valve injury measure: Active Infection measure: ECMO/Corvad setup time measure: Complete revascularization rate measure: Change in left ventricular ejection fraction (LVEF) from baseline measure: Change in New York Heart Association (NYHA) classification from baseline measure: Change in Seattle Angina Questionnaire (SAQ) score from baseline measure: Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline measure: Change in 5-level EQ-5D version (EQ-5D-5L) standardized health status scale score from baseline measure: Change in creatinine clearance rate from baseline measure: Stent thrombosis sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ling Tao status: RECRUITING city: Xi'an state: Shannxi zip: 710032 country: China name: Chao Gao, M.D., Ph.D. role: CONTACT phone: 86-18629551066 email: woshigaochao@gmail.com lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06373107 id: 2117651-2 briefTitle: Investigating Effects of High-intensity Gait Training on Gait, Balance and Depression Post-stroke overallStatus: NOT_YET_RECRUITING date: 2024-04-11 date: 2025-10-30 date: 2026-01-31 date: 2024-04-18 date: 2024-04-18 name: Alvernia University class: OTHER name: Lehigh Valley Health Network briefSummary: The purpose of this research is to study the improvements from walking practice that is vigorous enough to keep participants' heart rate over a certain target level during their physical therapy sessions. The investigators want to know about improvements in participants' walking function and mental health after 20 interventions. The study also aims to evaluate if participants' mental health, social support, and health literacy affect their attendance at physical therapy sessions. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: High intensity gait training measure: 3-meter backwards walk test measure: 6-minute walk test measure: 10-meter walk test measure: Surface electromyography (EMG) measure: Berg Balance Scale measure: Functional Gait Assessment measure: Borg Rating Scale of Perceived Exertion (RPE) measure: Patient Health Questionnaire (PHQ-9) measure: Rate of patient attendance (Compliance) to physical therapy measure: Newest Vital Sign measure: Multidimensional Scale of Perceived Social Support (MSPSS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lehigh Valley Health Network Outpatient Neurologic Rehab city: Allentown state: Pennsylvania zip: 18104-2310 country: United States name: Sandra M Tremblay, DPT role: CONTACT lat: 40.60843 lon: -75.49018 hasResults: False
nctId: NCT06373094 id: DON102-CTP briefTitle: A Single Dose Escalation Study of HHT201 in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-03-31 date: 2025-03-31 date: 2024-04-18 date: 2024-04-18 name: Shanghai Synergy Pharmaceutical Sciences Co., Ltd. class: INDUSTRY briefSummary: The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects. conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: Donepezil Dihydroxynaphthalate for Injection measure: Adverse events measure: Number of Participants With Abnormal Laboratory Values measure: Number of Participants With Abnormal ECG QT Interval measure: Number of Participants With Abnormal Vital signs measure: Number of Participants With Abnormal Physical examination measure: VAS measure: Cmax of Donepezil measure: Tmax of Donepezil measure: AUC0-t of Donepezil measure: AUC0-∞ of Donepezil measure: t1/2z of Donepezil measure: Vz/F measure: CLz/F sex: ALL minimumAge: 20 Years maximumAge: 59 Years stdAges: ADULT facility: Zhejiang Province Taizhou Hospital Luqiao Hospital (Enze Hospital) (Taizhou Hospital Phase I Center) city: Taizhou state: Zhe Jiang zip: 318000 country: China name: Donqing Lv role: CONTACT phone: 86-0576-85199816 email: lvdq@enzemed.com name: Zhanrong Ye role: CONTACT phone: 86-0576-85199816 email: Zoe.Ye@enzemed-crc.com lat: 32.49069 lon: 119.90812 hasResults: False
nctId: NCT06373081 id: CD19-CD3E-CN-A1 briefTitle: Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease overallStatus: RECRUITING date: 2024-04-20 date: 2025-04-15 date: 2026-04-15 date: 2024-04-18 date: 2024-04-18 name: Shanghai Changzheng Hospital class: OTHER briefSummary: This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases. conditions: Systemic Lupus Erythematosus (SLE) conditions: Sjogren's Syndrome conditions: Systemic Sclerosis conditions: Inflammatory Myopathy conditions: ANCA Associated Vasculitis conditions: Antiphospholipid Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: Anti-CD19-CD3E-CAR-T cells measure: The incidence of dose-limiting toxicities (DLTs) (Safety) measure: Proportion of patients for whom the desired dose of anti-CD19-CD3E-CAR-T cells can be successfully manufactured measure: Clinical response for relapsed/Refractory SLE measure: Clinical response for Sjögren's Syndrome measure: Clinical response for relapsed/refractory/progressive systemic sclerosis measure: Clinical response for relapsed/refractory/progressive inflammatory myopathy measure: Clinical response for relapsed/refractory anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: measure: Clinical response for relapsed/refractory/Catastrophic Antiphospholipid Syndrome sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai ChangZheng hospital status: RECRUITING city: Shanghai zip: 200003 country: China name: Huji Xu role: CONTACT phone: 86021-81885514 email: xuhuji@smmu.edu.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06373068 id: Resuscitation Orders ICU briefTitle: Association Between Resuscitation Orders and Mortality in ICU Patients overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2025-03 date: 2024-04-18 date: 2024-04-24 name: Karolinska Institutet class: OTHER briefSummary: The hypothesis of the study is that a resuscitation order other than full code is associated with increased mortality among critically ill patients. By incorporating conventional variables associated with death such as age, sex, and Simplified Acute Physiological Score, as well as including the new Clinical Frailty Scale in a statistical model, the aim is to investigate whether there is still an increased risk of death that remains unexplained. conditions: Critical Illness studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1500 type: ESTIMATED name: Resuscitation orders measure: Mortality sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373055 id: 4-2023-1232 briefTitle: Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics overallStatus: RECRUITING date: 2024-05-01 date: 2033-11 date: 2033-11 date: 2024-04-18 date: 2024-04-18 name: Yonsei University class: OTHER briefSummary: Although neoadjuvant chemotherapy in muscle-invasive bladder cancer has significantly improved oncological outcomes, approximately 50% of patients do not respond to neoadjuvant chemotherapy, which has adverse effects on patients by causing treatment toxicity and surgical delays. Therefore, treatment tailored specifically to the individual patient based on the genetic and/or molecular profile of the patient is urgently needed. Among patients scheduled for neoadjuvant chemotherapy, the investigators should differentiate between patients who will be highly effective with neoadjuvant chemotherapy and those who will not, and preferentially select other treatments including radical cystectomy in the patients with high probability of failure to neoadjuvant chemotherapy. However, there is no standard which patients would benefit from neoadjuvant chemotherapy. This study plans to predict treatment response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer by analyzing genetic and molecular profiles of tumor tissues obtained through transurethral bladder tumor resection. conditions: Muscle-invasive Bladder Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED name: neoadjuvant chemotherapy followed by radical cystectomy measure: Identification of responder to neoadjuvant chemotherapy by genetic and molecular profiles measure: overall survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy measure: cancer-specific survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy measure: progression-free survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy measure: recurrence-free survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea status: RECRUITING city: Seoul country: Korea, Republic of name: Won Sik Ham role: CONTACT phone: 02-2228-2310 email: uroham@yuhs.ac lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06373042 id: ADJUVANT-2 briefTitle: Tirofiban for Successful Endovascular Stroke Thrombectomy acronym: ADJUVANT-2 overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2026-07-31 date: 2026-10-31 date: 2024-04-18 date: 2024-04-18 name: Zhongming Qiu class: OTHER name: The Second Affiliated Hospital of Chongqing Medical University name: Mianyang Central Hospital name: The Second Hospital of Jiaozuo name: Chongzhou People's Hospital name: Xihua People's Hospital name: Xingguo People's Hospital briefSummary: Up to 50% of acute ischemic stroke patients with large vessel occlusion failed to achieve functional independence even after successful reperfusion therapy, a phenomenon that is referred to as "futile recanalization". The mechanism of futile recanalization is complex, and some studies have shown that it may be related to factors such as tissue no reflow, reocclusion, poor status of collateral circulation, hemorrhagic transformation, impaired cerebrovascular autonomic regulation, and low perfusion volume. Several studies suggested that maximizing the improvement of cerebral reperfusion is still the primary goal of acute large vessel occlusive stroke. Structural and functional alterations in the microvascular system may be a major obstacle to reperfusion. In animal models of cerebral ischemia, downstream microvascular thrombosis may occur in the early stage of cerebral ischemia and before vascular recanalization, which is the main factor leading to incomplete reperfusion and affecting the efficacy of endovascular thrombectomy.
Mechanical thrombectomy mainly addressed the occluded large arteries, and does not consider the distal arteries. However, the recanalization of occluded large arteries does not necessarily translate into successful reperfusion of the ischemic tissue supplied by the distal capillaries. Even with complete recanalization, impaired microcirculatory reperfusion may lead to poor clinical outcomes. Therefore, we speculate that at the end of endovascular thrombectomy, microthrombi remain present in the microcirculation of brain tissue in patients with complete or near-complete cerebral angiography, and that microthrombi is more likely to be dissolved than thrombus more proximal to the heart. Therefore, intra-arterial administration of pharmaceutical, such as tirofiban, may be the only possible option to ensure complete reperfusion of ischemic tissue. Tirofiban is a platelet glycoprotein IIb/IIIa receptor antagonist, which has been widely used in acute coronary syndrome, and its role in acute ischemic stroke has attracted more and more attention from stroke experts. Previous studies have suggested that tirofiban can further increase the incidence of successful recanalization, while reducing the reocclusion rate.
Whether early administration of intraarterial and intravenous tirofiban can further improve the clinical outcomes of patients with large vessel occlusive stroke after successful mechanical thrombectomy remains unclear. conditions: Stroke, Acute Ischemic studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 712 type: ESTIMATED name: Intraarterial and intravenous tirofiban name: Intraarterial and intravenous placebo measure: Functional independence measure: Recanalization on follow-up CTA or MRA measure: Early neurologic improvement measure: Level of disability measure: Excellent outcome measure: Independent ambulation measure: Health-related quality of life measure: Long-term of disability level measure: Health-related quality of life (long-term) measure: Incidence of symptomatic intracranial hemorrhage (SICH) measure: Radiologic intracranial hemorrhage rate measure: Mortality measure: Incidence of non-hemorrhagic serious adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373029 id: 2023PHB211-001(2) briefTitle: Deep-learning Enabled Ultrasound Diagnosis of Anterior Talofibular Ligament Injury overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-05-30 date: 2025-12-30 date: 2024-04-18 date: 2024-04-18 name: Peking University People's Hospital class: OTHER briefSummary: Ultrasound (US) is a more cost-effective, accessible, and available imaging technique to assess anterior talofibular ligament (ATFL) injuries compared with magnetic resonance imaging (MRI). However, challenges in using this technique and increasing demand on qualified musculoskeletal (MSK) radiologists delay the diagnosis. The investigators have already developed a deep convolutional network (DCNN) model that automates detailed classification of ATFL injuries. The investigators hope to use the DCNN in real-world clinical setting to test its diagnostic accuracy. conditions: Ultrasound conditions: Anterior Talofibular Ligament conditions: Deep Learning studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 400 type: ESTIMATED name: Ultrasound examination measure: classification of ATFL injury sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University People's Hospital city: Beijing state: Beijing zip: 100032 country: China lat: 39.9075 lon: 116.39723 hasResults: False